Submit your article to be part of our Special Collection led by Dr @DoreenLau4!. #CallForPapers 📩✨ molecular #imaging in #immunotherapy & image-guided drug delivery in cancer, infection & autoimmune disease. More details 🔗

🚨 Last chance! Just a few days left to submit to our Special Collection: Imaging in Immunotherapy. Showcase your research in molecular imaging, immune monitoring, and image-guided drug delivery. Deadline: June 2025 🧬🖼️ . 📩 Submit now:

🫁 New study: M2 macrophages ease asthma symptoms in mice by boosting IL-10⁺ B-cell production via the TGF-β & oxidative phosphorylation pathways. 💡 Highlights the regulatory role of macrophage–B cell interactions in asthma. 🔗 Read more:

🚨 Researchers at over 120 UK institutions can publish open access for free in Immunotherapy Advances! . No APCs, just impactful immunotherapy research shared with the world. 🌐 #OpenScience. 🔗Check eligibility here:

🔍 What do we really know about DC3s in solid tumors?. This new article explores the phenotype, function & impact of DC3s across cancers - highlighting their complex roles in both immunity & immunosuppression. 📖 Read it now: . #Immunotherapy.

🚨 Submit to the Immunotherapies for Inborn Errors of Immunity special collection!. We’re looking for research & reviews on targeted treatments, molecular pathways, and novel therapies for genetic immune disorders. 🗓️ Deadline: Sept 2025. 🔗

It’s #CervicalScreeningAwarenessWeek 🎗️. Tumour-reactive plasma cells fight HPV-driven cancers by making antibodies against HPV E2 proteins - offering new hope for personalized immunotherapy. 📖

June is #MyastheniaAwarenessMonth 🧠 #MAM2025. Regulatory B cells (Bregs) are key to immune balance, but in Myasthenia Gravis & other autoimmune diseases, their function falters. This review maps Breg heterogeneity & therapeutic potential. 📖

🧪 New in Immunotherapy Advances: A scalable 3D in vitro model mimics CTL exhaustion, enabling deeper insight into T cell suppression and therapeutic response. Essential reading for anyone developing CTL-targeting immunotherapies. 🔗 . #Immunotherapy

⏳ Last chance to submit!. Our special collection on Imaging in Immunotherapy closes end of June 2025. Don’t miss the opportunity to feature your research on molecular imaging, drug delivery & immune monitoring. 📢 Submit now:

🎉 The 2025 Oxford Cancer Immuno-Oncology Network Symposium is in full swing! @OxfordCancer . If you're attending, swing by our stand to chat all things Immunotherapy Advances - we'd love to connect!

Looking to publish your immunotherapy research? 🔬✨. We welcome rigorous studies from discovery to clinical trials, human or animal, positive or negative results - all with a translational focus. Fully Open Access & global reach!. Submit today:

Durvalumab after chemoradiotherapy boosts survival in stage III NSCLC patients. Real-world UK data supports PACIFIC trial findings. Treatment tolerance matters!. Explore here: . #Immunotherapy #CancerResearch.

🚨 Last chance to submit! The Imaging in Immunotherapy Special Collection closes end of June!. Got cutting-edge research on molecular imaging or image-guided drug delivery? Submit now and get extra promotion. 📩 More info//bit.ly/4j8c265 . #Immunotherapy

Whether discovery research, preclinical models, or clinical studies – Immunotherapy Advances welcomes your immunotherapy manuscript! 🧬🧪. Publish Open Access with expert editorial support. Submit today: . #Immunotherapy #CancerResearch #OpenAccess.

Attending the 3rd OCION Annual Symposium hosted by @oxfordcancer on 13 June in Oxford? 🚀. Don’t miss the chance to share your work with a wider audience - consider submitting your research to Immunotherapy Advances! 📢 . #OCION2025 #CancerResearch.

Peanut oral immunotherapy is showing promise in clinical trials, offering hope for safer desensitization in peanut-allergic individuals. But risks like serious reactions and patient anxiety remain. Optimized protocols are key. 🌰🧬. 🔗 . #Immunotherapy.

🧬 New in Immunotherapy Advances: CTLA-4 - two paths to anti-tumour immunity? . This review explores dual mechanisms of anti-CTLA-4 therapy and the emerging role of sCTLA-4 in shaping cancer immunotherapy. A must-read for checkpoint inhibitor research:

A phase 3 study in Japanese PID patients shows 20% subcutaneous immunoglobulin (Ig20Gly) given weekly or biweekly maintains protective IgG levels, the key antibody for infection defence - while showing a strong safety profile. Read more:

Immunotherapy Advances welcomes rigorous research spanning discovery, preclinical models & clinical trials - including negative results that advance immune-mechanistic insights. Submit your work today:

RT @OxfordJournals: Don't miss your last chance to get involved in @IMTadvances's upcoming collection on B cell and immune regulation 🧫 Top….